Lipocine (NASDAQ:LPCN) CEO Mahesh Patel Acquires 25,000 Shares of Stock

Lipocine Inc. (NASDAQ:LPCN) CEO Mahesh Patel bought 25,000 shares of the company’s stock in a transaction on Monday, April 6th. The stock was bought at an average cost of $2.03 per share, for a total transaction of $50,750.00. Following the completion of the transaction, the chief executive officer directly owned 160,679 shares of the company’s stock, valued at $326,178.37. This trade represents a 18.43% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Lipocine Price Performance

Shares of NASDAQ LPCN opened at $1.94 on Tuesday. Lipocine Inc. has a 1-year low of $1.81 and a 1-year high of $12.37. The business’s fifty day moving average price is $8.10 and its two-hundred day moving average price is $5.78. The firm has a market capitalization of $14.16 million, a PE ratio of -1.15 and a beta of 1.09.

Lipocine (NASDAQ:LPCN) last released its quarterly earnings results on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.26. Lipocine had a negative return on equity of 59.30% and a negative net margin of 487.00%.The company had revenue of $1.15 million during the quarter, compared to analysts’ expectations of $0.12 million.

Institutional Trading of Lipocine

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Boothbay Fund Management LLC acquired a new position in Lipocine during the fourth quarter worth $441,000. Squadron Capital Management LLC bought a new position in shares of Lipocine during the fourth quarter valued at $4,256,000. Diadema Partners LP bought a new position in shares of Lipocine during the fourth quarter valued at $2,095,000. Ikarian Capital LLC acquired a new stake in shares of Lipocine during the 4th quarter worth about $1,602,000. Finally, Geode Capital Management LLC increased its position in shares of Lipocine by 2.2% during the 4th quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock worth $502,000 after purchasing an additional 1,374 shares in the last quarter. Institutional investors and hedge funds own 9.11% of the company’s stock.

Wall Street Analyst Weigh In

LPCN has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “neutral” rating on shares of Lipocine in a research report on Monday. Wall Street Zen upgraded Lipocine from a “sell” rating to a “hold” rating in a research report on Sunday, March 22nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Lipocine in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Lipocine currently has an average rating of “Hold” and an average target price of $15.00.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.